Ipraalox

Pantoprazole, the active ingredient in Ipraalox, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Ipraalox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Pantoprazole is used to treat acid‑related disorders of the upper gastrointestinal tract.

- Gastroesophageal reflux disease (GERD): reduces acid exposure, promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal repair and alleviates symptoms. - Peptic ulcer disease: promotes ulcer healing by suppressing gastric acid production. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Pantoprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild pain in the head region. - Diarrhea: loose, watery stools. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of sickness. - Flatulence: excess intestinal gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe colitis with diarrhea. - Elevated liver enzymes: signs of hepatic injury. - Low magnesium levels: muscle cramps, irregular heartbeat. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder.

Before prescribing Pantoprazole, clinicians should consider several precautionary measures.

- Assess renal function: adjust dosage in patients with severe impairment. - Monitor magnesium levels: prolonged therapy may cause hypomagnesemia. - Use cautiously in hepatic disease: drug is metabolized in the liver. - Avoid in known hypersensitivity to PPIs: discontinue if allergic reaction occurs. - Pregnancy category B: weigh potential benefits against risks. - Store below 25°C: keep in the original pack, protect from moisture.

Pantoprazole can affect the pharmacokinetics of several concomitant medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Methotrexate: reduced clearance, risk of toxicity. - Digoxin: increased serum concentration, monitor for signs of toxicity.